Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1863-4362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients ; day:27 ; month:1 ; year:2022 ; pages:1-7
Irish journal of medical science ; (27.1.2022), 1-7
- Creator
-
Li, Ningjie
Chen, Jiao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11845-021-02884-w
- URN
-
urn:nbn:de:101:1-2022041708491487791297
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Ningjie
- Chen, Jiao
- SpringerLink (Online service)
Other Objects (12)
Konventionelle versus Drug-Eluting Beads transarterielle Chemoembolisation (cTACE vs. DEB-TACE) beim hepatozellulärem Karzinom mit Pfortaderthrombose
Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
Tace molesta tace fastidiosa diva
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE
Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE)
TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
The Role of conventional TACE (cTACE) and DEBIRI-TACE in colorectal cancer liver metastases
Konventionelle versus Drug-Eluting Beads transarterielle Chemoembolisation (cTACE vs. DEB-TACE) beim hepatozellulärem Karzinom mit Pfortaderthrombose
Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
Tace molesta tace fastidiosa diva
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE
Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE)
TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
The Role of conventional TACE (cTACE) and DEBIRI-TACE in colorectal cancer liver metastases
Konventionelle versus Drug-Eluting Beads transarterielle Chemoembolisation (cTACE vs. DEB-TACE) beim hepatozellulärem Karzinom mit Pfortaderthrombose
Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
Tace molesta tace fastidiosa diva
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE
Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE)
TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma